Home / Restatements / NEUROONE MEDICAL TECHNOLOGIES Corp
Filed 2026-05-22 路 Form 8-K 路 Accession 0001213900-26-060600 nano
Price before filing: $3.9 (2026-05-21 close, split/dividend-adjusted)
Market cap at flag: $31.1M (2026-05-22) 路 Latest: $8.3M (2026-10-16)
| Window | NMTC | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | -16.7% | +0.5% | -17.1% | 2026-06-22 |
| 90 days | -44.9% | +2.9% | -47.8% | 2026-08-20 |
| 180 days | pending | pending | until 2026-11-18 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
90 days before the flag: 1 insider sold $23K (5 sales); 1 insider bought $670K (1 purchase)
30 days after: none reported.
| Date | Insider | Type | Shares | Price | Value | 10b5-1 plan | Source |
|---|---|---|---|---|---|---|---|
| 2026-03-01 | Wambeke David J. Chief Business Officer | Purchase | 1,000,000 | $0.67 | $670K | no | Form 4 |
| 2026-03-10 | Christianson Mark Business Development Director | Sale | 11,611 | $0.80 | $9K | no | Form 4 |
| 2026-03-11 | Christianson Mark Business Development Director | Sale | 2,109 | $0.80 | $2K | no | Form 4 |
| 2026-03-12 | Christianson Mark Business Development Director | Sale | 817 | $0.80 | $654 | no | Form 4 |
| 2026-03-13 | Christianson Mark Business Development Director | Sale | 100 | $0.80 | $80 | no | Form 4 |
| 2026-03-30 | Christianson Mark Business Development Director | Sale | 15,363 | $0.74 | $11K | no | Form 4 |
| 2026-05-22: red flag filed | |||||||
Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2026-02-21 to 2026-06-21. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.
"On May 21, 2026, the Audit Committee (the "Audit Committee") of the Board of Directors of NeuroOne Medical Technologies Corporation (the "Company"), after discussion with management, determined that the Company's previously issued interim financial statements included in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed on May 12, 2026 (the "Previous Filing"), should no longer..."
Quoted from the filing. Source
The company says previously issued financial statements (or the auditor's report on them) should no longer be relied upon (8-K Item 4.02). Non-reliance on the financial statements themselves is one of the most serious accounting red flags: past reported numbers were wrong and will be restated.
Scope: previously issued financial statements
Why this score: also within 90 days: Going-concern doubt
Read the original filing on SEC.gov →
🔔 Get email alerts for this company
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.